share_log

Cantor Fitzgerald Reiterates Overweight on Vera Therapeutics, Maintains $107 Price Target

Benzinga ·  Oct 1 20:16  · Ratings

Cantor Fitzgerald analyst Pete Stavropoulos reiterates Vera Therapeutics (NASDAQ:VERA) with a Overweight and maintains $107 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment